Costs in Different States of Breast Cancer

被引:7
|
作者
Roine, Eija [1 ,2 ]
Farkkila, Niilo [3 ]
Sintonen, Harri [3 ]
Taari, Kimmo [2 ,4 ]
Roine, Risto P. [2 ,5 ,6 ]
Saarto, Tiina [1 ,2 ]
机构
[1] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
[2] Univ Helsinki, Helsinki, Finland
[3] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
[4] Helsinki Univ Hosp, Dept Urol, Helsinki, Finland
[5] Helsinki Univ Hosp, Adm, Helsinki, Finland
[6] Univ Eastern Finland, Dept Social & Hlth Management, Kuopio, Finland
关键词
Burden of disease; costs; direct costs; indirect costs; resource use; breast cancer; QUALITY-OF-LIFE; COLORECTAL-CANCER; PROSTATE;
D O I
10.21873/anticanres.13119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This cross-sectional study estimated direct cancer-related health care, productivity and informal care costs for a six-month period for different states of breast cancer (BC). Patients and Methods: A total of 827 BC patients answered a questionnaire enquiring about informal care, work capacity, and demographic factors. Direct health care resource use and productivity costs were obtained from registries. Mutually exclusive groups were formed based on disease state and time from diagnosis: primary treatment (first six months after diagnosis), rehabilitation (>six months after diagnosis), remission (>1.5 years after diagnosis), and metastatic. Results: Mean total costs were: primary treatment (sic)22,876, rehabilitation (sic)3,456, remission (sic)1,728, and metastatic (sic)24,320. Mean direct health care costs were: primary treatment (sic)11,798, rehabilitation (sic)2,398, remission (sic)1,147, and metastatic (sic)13,923. Mean productivity costs varied between 18-39% and indirect costs (productivity and informal care costs) between 31-48% of the total costs. Conclusion: Direct medical costs were highest, but indirect costs constituted up to half of the total costs and are essential when estimating the total cost burden, as many patients are of working age.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 50 条
  • [21] Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer
    Frederix, G. W. J.
    Severens, J. L.
    Hovels, A. M.
    van Hasselt, J. G. C.
    Raaijmakers, J. A. M.
    Schellens, J. H. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 489 - 495
  • [22] Interval breast cancer: is it a different type of breast cancer?
    Raja, MAK
    Hubbard, A
    Salman, AR
    BREAST, 2001, 10 (02): : 100 - 108
  • [23] Direct medical costs of managing toxicities related to taxane therapy for metastatic breast cancer in the United States
    Bramley, TJ
    Vishalpura, TT
    Nightengale, BS
    VALUE IN HEALTH, 2004, 7 (03) : 250 - 250
  • [24] HOSPITAL UTILIZATION AND COSTS OF MALE BREAST CANCER PATIENTS IN THE UNITED STATES: AN ANALYSIS OF NATIONWIDE INPATIENT SAMPLE
    Park, S. K.
    Ng, B. P.
    Chun, H. K.
    Park, C.
    VALUE IN HEALTH, 2020, 23 : S89 - S89
  • [25] Costs and quality of life in metastatic breast cancer
    ReboulMarty, J
    Launois, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : OP24 - OP24
  • [26] COSTS AND BENEFITS OF BREAST-CANCER DIAGNOSIS
    LEIVONEN, M
    ACTA ONCOLOGICA, 1987, 26 (04) : 257 - 260
  • [27] Direct costs of breast cancer care in Colombia
    Gamboa, Oscar
    Angelica Buitrago, Lina
    Lozano, Teofilo
    Dieleman, Sabrina
    Gamboa, Carlos
    Leon Guzman, Erika
    Gil, Milena
    Fuentes, Juan
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2016, 20 (02): : 52 - 60
  • [28] Costs of breast cancer treatment in the United Kingdom
    Dolan, P
    Torgerson, DJ
    Wolstenholme, J
    BREAST, 1999, 8 (04): : 205 - 207
  • [29] THE COSTS OF BREAST CANCER PRIOR TO AND FOLLOWING DIAGNOSIS
    Broeckx, S.
    Den Hond, E.
    Torfs, R.
    D'Hooghe, T.
    Simoens, S.
    VALUE IN HEALTH, 2009, 12 (07) : A266 - A266
  • [30] Costs and benefits of diagnosing familial breast cancer
    Moller, P
    ANNALS OF ONCOLOGY, 2004, 15 : I55 - I59